868 related articles for article (PubMed ID: 33925129)
41. Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.
Stark M; Assaraf YG
Oncotarget; 2017 Jul; 8(30):49973-49987. PubMed ID: 28637003
[TBL] [Abstract][Full Text] [Related]
42. The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy.
Liu S; Khan AR; Yang X; Dong B; Ji J; Zhai G
J Control Release; 2021 Jul; 335():1-20. PubMed ID: 33991600
[TBL] [Abstract][Full Text] [Related]
43. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
Tekchandani P; Kurmi BD; Paliwal SR
Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
[TBL] [Abstract][Full Text] [Related]
44. Zinc Oxide Nanoparticles as Adjuvant To Facilitate Doxorubicin Intracellular Accumulation and Visualize pH-Responsive Release for Overcoming Drug Resistance.
Liu J; Ma X; Jin S; Xue X; Zhang C; Wei T; Guo W; Liang XJ
Mol Pharm; 2016 May; 13(5):1723-30. PubMed ID: 27070828
[TBL] [Abstract][Full Text] [Related]
45. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
46. Theranostic micelles combined with multiple strategies to effectively overcome multidrug resistance.
Zhao D; Chen Q; Song H; Luo S; Ge P; Wang Y; Ma J; Li Z; Gao X; Zhao X; Subinuer X; Yang H; Jiang X; Chen Y; Zhu X
Nanomedicine (Lond); 2018 Jul; 13(13):1517-1533. PubMed ID: 30028224
[TBL] [Abstract][Full Text] [Related]
47. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
Wei G; Yang G; Wei B; Wang Y; Zhou S
Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
[TBL] [Abstract][Full Text] [Related]
48. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
Kibria G; Hatakeyama H; Harashima H
Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
[TBL] [Abstract][Full Text] [Related]
49. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
Miller-Kleinhenz JM; Bozeman EN; Yang L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
[TBL] [Abstract][Full Text] [Related]
50. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
51. Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer.
Cao Y; Meng F; Cai T; Gao L; Lee J; Solomevich SO; Aharodnikau UE; Guo T; Lan M; Liu F; Li Q; Viktor T; Li D; Cai Y
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1950. PubMed ID: 38528388
[TBL] [Abstract][Full Text] [Related]
52. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
[TBL] [Abstract][Full Text] [Related]
53. Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor.
Che L; Liu Z; Wang D; Xu C; Zhang C; Meng J; Zheng J; Yuan H; Zhao G; Zhou X
Acta Biomater; 2019 Oct; 97():461-473. PubMed ID: 31344512
[TBL] [Abstract][Full Text] [Related]
54. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
Petrikaite V; D'Avanzo N; Celia C; Fresta M
Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
[TBL] [Abstract][Full Text] [Related]
55. Nanotechnologies for the treatment of colon cancer: From old drugs to new hope.
Kotelevets L; Chastre E; Desmaƫle D; Couvreur P
Int J Pharm; 2016 Nov; 514(1):24-40. PubMed ID: 27863668
[TBL] [Abstract][Full Text] [Related]
56. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
57. Photo-responsive prodrug nanoparticles for efficient cytoplasmic delivery and synergistic photodynamic-chemotherapy of metastatic triple-negative breast cancer.
Jiao J; Lu H; Wang S
Acta Biomater; 2021 May; 126():421-432. PubMed ID: 33774201
[TBL] [Abstract][Full Text] [Related]
58. Gd-based upconversion nanocarriers with yolk-shell structure for dual-modal imaging and enhanced chemotherapy to overcome multidrug resistance in breast cancer.
Pan Y; Zhang L; Zeng L; Ren W; Xiao X; Zhang J; Zhang L; Li A; Lu G; Wu A
Nanoscale; 2016 Jan; 8(2):878-88. PubMed ID: 26648267
[TBL] [Abstract][Full Text] [Related]
59. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
60. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]